Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12648363 | 0.93 | EPHX1 (0.87) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL6047362 | 0.89 | EPHX1 (1.00) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL22754575 | 0.89 | EPHX1 (1.00) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL3839853 | 0.89 | EPHX1 (1.00) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL657100 | 0.89 | EPHX1 (1.00) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL3839852 | 0.89 | EPHX1 (1.00) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL11492082 | 0.86 | EPHX1 (0.79) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL7775683 | 0.84 | EPHX1 (0.77) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL7112702 | 0.84 | EPHX1 (0.77) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL7110543 | 0.84 | EPHX1 (0.77) | EPHX1MEN1KMT2ATP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575489-A2 | USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO INHIBIT VASCULAR SMOOTH MUSCLE CELL PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-21 | — | — | EP | claimed |
| EP-0926951-B1 | TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS | UNIV CALIFORNIA (US) | 2004-04-21 | — | — | EP | claimed |
| WO-2003061597-A2 | USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO INHIBIT VASCULAR SMOOTH MUSCLE CELL PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-07-31 | — | — | WO | claimed |
| US-20030139469-A1 | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-07-24 | — | — | US | claimed |
| EP-0926951-A4 | METHODS OF TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS | UNIV CALIFORNIA (US) | 2001-08-08 | — | — | EP | claimed |
| EP-0926951-A1 | METHODS OF TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-07-07 | — | — | EP | claimed |
| WO-1998006261-A1 | METHODS OF TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-02-19 | — | — | WO | claimed |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250161334-A1 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | PEYMAN GHOLAM A (US) | 2025-05-22 | — | — | US | disclosed |
| US-12251379-B2 | Methods of inhibiting formation of alpha synuclein aggregates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-18 | — | — | US | disclosed |
| US-12226478-B2 | Method of treating, reducing, or alleviating a medical condition in a patient | PEYMAN GHOLAM A (US) | 2025-02-18 | — | — | US | disclosed |
| US-20230338520-A1 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | PEYMAN GHOLAM A (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2003061597-A2 | USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO INHIBIT VASCULAR SMOOTH MUSCLE CELL PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20030139469-A1 | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-07-24 | — | — | US | disclosed |
| EP-0926951-A4 | METHODS OF TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS | UNIV CALIFORNIA (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000023060-A2 | METHOD OF TREATING IMMUNOLOGICAL DISORDERS MEDIATED BY T-LYMPHOCYTES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-04-27 | — | — | WO | disclosed |
| US-5955496-A | TREATING ADULT RESPIRATORY DISTRESS SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-21 | — | — | US | disclosed |
| EP-0926951-A1 | METHODS OF TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998006261-A1 | METHODS OF TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12357598-B2 | Treatment of neurodevelopmental disorders | FABP7, ADH1B, ELOVL1 | EPHX1 25/4885MEN1 4869/4885KMT2A 1026/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | EPHX1 8/4885MEN1 4855/4885KMT2A 1497/4885 |
| US-12251379-B2 | Methods of inhibiting formation of alpha synuclein aggregates | SNCA, PARK7, PYGB | EPHX1 3353/4885MEN1 4097/4885KMT2A 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.